anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
People with diabetes are at risk for life-altering complications and comorbidities. One of the most serious complications is a diabetic foot ulcer, which significantly increases risk for limb amputation. To heal a diabetic foot ulcer, patients are often instructed to refrain from bearing weight on the affected limb. This non-weight bearing protocol results in extended periods of inactivity that can lead to severe physical deconditioning, including diminished strength, endurance, and flexibility. EnhanceFitness, a community exercise program designed for older adults, holds classes that can be adapted for people who are non-weight bearing due to a healing foot ulcer. These exercise classes focus specifically on strength training, aerobic fitness, and stretching - activities that can counteract progressive deconditioning in people with diabetic foot ulcer. Health benefits associated with exercise in people with diabetes are well-established. However, for those experiencing declines in health and physical function because of healing protocols for a diabetic foot ulcer, the potential benefits of exercise are not yet known. The proposed project aims to address this gap in diabetes research.

The long-term goal of this research is to improve the health and quality of life of people with complications from diabetes. The specific goal of this project is to evaluate the effect of a seated community exercise program, EnhanceFitness, on clinically-meaningful outcomes in people with diabetic foot ulcers. Study investigators will recruit people with diabetic foot ulcers from local wound care clinics and randomly assign them to two groups. The first group will engage in EnhanceFitness, an existing community fitness program appropriate for people with weight-bearing restrictions due to wound-healing protocols. The second group will receive the standard of care, which does not include exercise recommendations. To assess the effectiveness of the seated exercise program, the investigators will compare important health outcomes between people with diabetic foot ulcers participating in EnhanceFitness and a control group with diabetic foot ulcers. Specifically, the investigators will assess physical and physiological outcomes, including glycated hemoglobin (HbA1c), lower-extremity strength, and wound healing. The investigators will also measure psychosocial outcomes, such as depression, perceived physical function, overall health, and self-reported ability to continue with exercise. Further, the investigators will evaluate the feasibility of conducting research assessing the effects of seated exercise in people with foot ulcers. The data collected in this pilot research will be used to apply for large, extramural funding that aims to mitigate physical deconditioning in people with diabetic foot ulcers.
Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
The invention relates to an eye drop nursing product for improving dry eyes, which aims to solve the problems of insecurity and dependence of the existing product for improving or maintaining eyesight problems. 1. The invention is suitable for solving the problems of dry eyes and clean eyeballs at any time in different scenes; 2. the raw materials of the invention adopt pharmaceutical grade hyaluronic acid for moistening eyes, and the wild chrysanthemum extract and the andrographis paniculata extract aim at hot air and inflammation generated by light energy damage. The product is mild, anti-inflammatory and bactericidal, reduces air bacteria, inhibits germs and blocks germs from entering eyes; 3. for similar products, the eye care product not only realizes the traditional effect, but also can maintain the eye health, and the addition of the human anthocyanin can prevent the damage of light energy to the eyes. 4. Compared with the prior art, the eye washing liquid has the advantages that 1, compared with Japanese anti-growth tears, the eye washing liquid can moisten eyes, has the effects of eliminating red blood filaments and yellow gas of the eyes better than Japanese anti-growth tears, has the effect of eliminating 2, is closer to tear liquid component 3 than eye washing liquid mainly aiming at eye washing, can calm and diminish inflammation more safely than other eye washing liquid, and can protect eye cells by resisting light.
FIELD: food industry. SUBSTANCE: emulsion contains water, fat, and protein composition of lupine. The latter contains less than 65% of lupine protein and also includes other, non-protein lupine components, endogenous enzymes in lupine protein composition being inactivated. Emulsion or gel serve for preparing functional food component, edible product, beverage, animal fodder, and cosmetic agent. Emulsion preparation method comprises preparing protein composition of lupine, mixing protein composition with oil and water, and emulsifying mixture. Gel preparation method comprises providing protein composition of lupine, mixing protein composition with water, and gelating mixture. EFFECT: enhanced oil-binding capacity at relatively low level of lupine protein composition (less than 65%) and enabled stabilization of emulsion at higher content of oil. 45 cl, 3 ex
In this work we will utilize conventional magnetic resonance imaging as well as a set of advanced magnetic resonance imaging tools to investigate changes in tumor physiology and the human brain resulting from anthracycline-based systemic chemotherapy. We will recruit up to 15 subjects diagnosed with breast cancer and preparing for an anthracycline-based systemic chemotherapy regimen. Each subject will undergo the set of MR imaging tools before therapy, after one therapy session, after four therapy sessions, and at the conclusion of therapy. Conventional MRI methods will be used to quantify tumor-response to chemotherapy for each subject. A control group of up to 15 normal subjects will also be recruited and will undergo MR brain imaging twice with a gap of 6 months between scans. All subjects will also undergo a battery of neuropsychological tests at each imaging session. The results of the neuropsychological tests will be used to quantify cognitive changes for each subject. A final analysis will determine if the advanced MR modalities can be used to predict the response of tumors or human cognition to chemotherapy.
Atrial fibrillation (AF), the most common arrhythmia, accounts for 1/3rd of Cardiovascular expenses, with over 10 millions affected in Europe. In addition to significant impact on quality of life, AF exposes patients to stroke, heart failure, dementia and death. AF is the most commonly ablated arrhythmia. The Pulmonary Vein Isolation (PVI) is the cornerstone of AF ablation, preventing recurrences, especially in patients with persistent AF. Catheter ablation of AF uses either radiofrequency (RF) or cryothermal (cryo) energy. Common to these thermal energy sources is their reliance on time-dependent conductive heating/cooling and the fact that these modalities ablate all tissue types indiscriminately. The ablation procedure remains long, requires skills and expertise, and has a limited success rate, mostly because of non-durable lesions after PVI implying frequent redo procedures. And these energies are associated with rare but severe complications due to their thermal nature. The goal of BEAT AF is to disrupt AF ablation by achieving durable PVI with permanent, coalescent and transmural ablation lesions using Pulsed Electric Field (PEF) energy. PEF is non-thermal and creates nanoscale pores in cell membranes. Cardiac cells are highly sensitive to PEF unlike phrenic and oesophageal cells. BEAT AF aims to allow assessing preliminary evidence of efficacy and safety of pulsed field energy in persistent AF ablation. For this purpose, a randomized clinical trial will be conducted to provide large clinical data of PEF of 1-year recurrence for persistent AF. The BEAT AF consortium gathers 9 European renowned clinical centres (France, Czech Republic, Germany, Austria, Belgium) to contribute to decrease the huge burden of AF.
Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
Genital warts (GW; also called condylomas or condylomata acuminata) are lesions caused by infection of Human papillomavirus (HPV)(specifically HPV-6 or HPV-11 types, found in \> 95% of lesions). GW are sexually transmitted and affect about 1% of the sexually active population. GW represent a distressful condition for social and sexual life, especially in the cases of external condylomas. No HPV-specific antiviral treatment exists to date, and all existing therapies (either surgical or drug) have limited efficacy, with a significant level of GW recurrences and are associated with local skin reactions. AP611074 is a synthetic new chemical entity that is a potent and selective inhibitor of the interaction between two viral proteins from HPV6 and HPV11, an interaction that is a necessary step for HPV DNA replication and thus viral production. AP611074 is the "first in class" specific HPV antiviral described to treat condyloma caused by HPV infection.
Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
BACKGROUND: Chronic pancreatitis (CP) is a progressive disease characterized by pancreatic fibrosis for which effective treatment options are lacking. Mesenchymal stem cells (MSCs) have shown potential for fibrosis treatment but face limitations in clinical application. The high-mobility group box 1 (HMGB1) fragment mobilizes MSCs from bone marrow into the blood and has emerged as a promising therapeutic agent for tissue regeneration in various pathological conditions. The aim of this study was to investigate the potential therapeutic effects of systemic administration of the HMGB1 fragment in a mouse model of CP.
METHODS: A caerulein-induced CP mouse model was used, and the HMGB1 fragment was administered by tail vein injection. Parameters such as body weight, pancreatic tissue damage, fibrosis, inflammatory cytokine expression, and collagen-related gene expression were evaluated using various assays, including immunohistochemistry, real-time PCR, serum analysis, and single-cell transcriptome analysis. And the migration of MSCs to the pancreas was evaluated using the parabiosis model.
RESULTS: Administration of the HMGB1 fragment was associated with significant improvements in pancreatic tissue damage and fibrosis. It suppressed the expression of inflammatory cytokines and activated platelet-derived growth factor receptor-α+ MSCs, leading to their accumulation in the pancreas. The HMGB1 fragment also shifted gene expression patterns associated with pancreatic fibrosis toward those of the normal pancreas. Systemic administration of the HMGB1 fragment demonstrated therapeutic efficacy in attenuating pancreatic tissue damage and fibrosis in a CP mouse model.
CONCLUSION: These findings highlight the potential of the HMGB1 fragment as a therapeutic target for the treatment of CP.
The present invention relates to a traditional Chinese medicine formula for treating cysticercosis. A honeyed pill is refined by preparing the twenty traditional Chinese medicines of herba agastachis, cassia twig, concha haliotidis, wrinkled giant-hyssop, etc. according to a proportion by weight. The present invention treats the root causes of diseases by taking insecticide as a principal medicine and taking dead worm absorption medicines as minister medicines. The present invention treats the manifestations of diseases by performing the functions of tranquilizing spirit, relieving spasm, lowering intracranial hypertension, dredging the channel, protecting the heart, the liver, the kidney and other organs, assisting self physiological functions, repairing the cranial nerve, recovering memory, etc. The present invention treats both the manifestations and the root causes of diseases. The inventor treats more than thirty thousand patients with various kinds of brain cysticercosis since 1960 to 2005, and long-range therapeutic effect, metaphase therapeutic effect, recent therapeutic effect, efficiency and curative rate are extremely ideal. The contrast of the prophase CT picture, the metaphase picture and the anaphase picture of the treatment verifies that live biadder worms are killed in 3 months, paroxysmal exudation is absorbed, a low-density focus is converted into a high-density focus, and the high-density focus is infiltrated until images disappear. Patients recover after 6 months, the patients are rechecked by CT after treatment courses are over, the high-density focus disappears, and the patients are clinically healed. The verification proves the present invention has strong worm extermination capability and dead worm absorption capability during the bladder worm treatment.
OBJECTIVE: Within the spectrum of developmental and epileptic encephalopathy (DEE), there are a group of infants with features that are distinct from the well-recognized syndromes of early infantile developmental and epileptic encephalopathy (EIDEE), infantile epileptic spasm syndrome (IESS), and Lennox-Gastaut syndrome (LGS). We refer to this condition as late infantile epileptic encephalopathy (LIEE). Our objective was to highlight the characteristics of this group by analyzing patients who exhibit prototypical features.
METHODS: From July 2022 to May 2023, we searched for LIEE features in pediatric patients who underwent epilepsy follow-up at the University of Chicago Comer Children's Hospital.
RESULTS: Out of 850 patients evaluated, thirty patients (3.5%) were identified with LIEE based on electroclinical characteristics. These patients had an average onset of epilepsy at 6.8 months and an average onset of LIEE features at 18.1 months. The epilepsy etiology was most commonly genetic and metabolic (50%), followed by congenital cortical malformations (23%), acquired structural abnormalities (20%), and unknown (7%). The predominant seizure types were myoclonic-tonic (70%), spasm-tonic (50%), epileptic spasms (47%), tonic (43%), and myoclonic (43%) seizures. All patients reported a history of either spasm-tonic or myoclonic-tonic seizures in addition to other types. All patients had EEGs showing discontinuity, electrodecrements, or both along with diffuse slowing, background voltages between 100 and 300 μV, and superimposed multifocal, diffuse epileptiform discharges. Every patient, except one, fulfilled the definition of drug-resistant epilepsy, and all reported either moderate-to-severe or severe developmental delay.
SIGNIFICANCE: Late infantile epileptic encephalopathy (LIEE) is characterized by several unique clinical and electrographic features. Typically, LIEE manifests in patients during the second year of life and occurs before two years of age, hence late infantile onset. The condition is commonly observed in infants with symptomatic epilepsy. Myoclonic-tonic and spasm-tonic seizures are the quintessential seizure types. The inter-ictal EEG exhibits more organization and lower voltages than seen with hypsarrhythmia and lacks the defining EEG characteristics of EIDEE, IESS, or LGS. We propose that LIEE is a distinct electroclinical syndrome within the spectrum of developmental and epileptic encephalopathies.
Healthcare discriminations based on one's ethnic background is increasingly being studied in medicine. The scale of the Covid-19 pandemic has played an important role in bringing them to light. Data, although scarce, exist in France. These discriminations have an impact on the care pathway and contribute to the renunciation of care by the most affected populations. The issue of discrimination is particularly relevant in infectious diseases. Although the epidemiology of infectious diseases is unevenly distributed worldwide, erroneous social representations are prevalent and expose to a harmful prejudice against migrants with regard to infectious diseases. The transmissible nature of some infectious diseases reinforces their stigmatizing potential. In this context, it seems important to discuss the dimension to be given to social determinants, geographical origin, phenotype, and ethnicity in teaching and medical reasoning. The English-speaking world uses the concept of "race" in a structural way, whereas this "international standard" has not been applied in France until now. To improve the care of people from minority groups, it seems important to better document and teach a more nuanced clinical reasoning based on origin, without neglecting the importance of collecting and taking into account social determinants of health and environmental factors.
KEY POINTS: Information on metabolomic profiles in kidney stone formers is limited. This article describes investigations of associations between plasma metabolomic profiles and the risk of incident, symptomatic kidney stones. Three novel metabolites had negative associations with kidney stones: β-cryptoxanthin and two forms of sphingomyelin.
BACKGROUND: Information on metabolomic profiles in kidney stone formers is limited. To examine independent associations between plasma metabolomic profiles and the risk of incident, symptomatic kidney stones in adults, we conducted prospective nested case-control studies in two large cohorts.
METHODS: We performed plasma metabolomics on 1758 participants, including 879 stone formers (346 from the Health Professionals Follow-Up Study [HPFS] cohort, 533 from the Nurses' Health Study [NHS] II cohort) and 879 non–stone formers (346 from HPFS, 533 from NHS II) matched for age, race, time of blood collection, fasting status, and (for NHS II) menopausal status and luteal day of menstrual cycle for premenopausal participants. Conditional logistic regression models were used to estimate the odds ratio (OR) of kidney stones adjusted for body mass index; hypertension; diabetes; thiazide use; and intake of potassium, animal protein, oxalate, dietary and supplemental calcium, caffeine, and alcohol. A plasma metabolite–based score was developed in each cohort in a conditional logistic regression model with a lasso penalty. The scores derived in the HPFS ("kidney stones metabolite score [KMS]_HPFS") and the NHS II ("KMS_NHS") were tested for their association with kidney stone risk in the other cohort.
RESULTS: A variety of individual metabolites were associated with incident kidney stone formation at prespecified levels of metabolome-wide statistical significance. We identified three metabolites associated with kidney stones in both HPFS and NHS II cohorts: β-cryptoxanthin, sphingomyelin (d18:2/24:1, d18:1/24:2), and sphingomyelin (d18:2/24:2). The standardized KMS_HPFS yielded an OR of 1.23 (95% confidence interval, 1.05 to 1.44) for stones in the NHS II cohort. The standardized KMS_NHS was in the expected direction but did not reach statistical significance in HPFS (OR, 1.16; 95% confidence interval, 0.97 to 1.39).
CONCLUSIONS: The findings of specific metabolites associated with kidney stone status in two cohorts and a plasma metabolomic signature offer a novel approach to characterize stone formers.
A CD recorded by the Turkish Psychological Association was provided to RM group participants. It consists of 30 minutes relaxing music only. The participant was asked to just listen to music with without working in a private room.
OBJECTIVE: To explore the combined efficacy of modified Yangxin Anshen decoction and Western medicine treatment in elderly patients with schizophrenia and sleep disorders.
METHODS: A total of 144 elderly patients with schizophrenia and sleep disorders in Wuhan Wudong Hospital were enrolled as participants in this study from April 2021 to April 2022. The participants were randomly and equally divided into a control group (receiving conventional Western medicine treatment) and two study groups: study group 1 received modified Yangxin Anshen decoction, and study group 2 receive modified Yangxin Anshen decoction in addition to Western medicine treatment. TCM syndrome scores, sleep quality, polysomnography, serum levels of 5-HT, DA, and MT were compared between the two groups. Moreover, the efficacy and adverse reactions were recorded.
RESULTS: After four weeks of treatment, the efficacy of study group 2 was significantly better than that of the control group and Study Group 1 (P < .05). There was no statistically significant difference between the three groups in secondary and main symptoms before treatment (P >.05), while the secondary and main symptoms of study group 2 were significantly lower than those of the control group and study group 1 after four weeks of treatment (P < .05). Before treatment, no statistically significant difference was found in sleep quality score between the three groups (P > .05), whereas the index of the study group 2 was evidently lower than that of the control group and study group 1 after four weeks of treatment (P < .05). Before treatment, there was no significant difference in terms of total recording time, total sleep time, sleep onset latency, sleep efficiency, and four stages (N1, N2, N3, and REM) between the three groups (P > .05). After four weeks of treatment, although no statistically significant difference was shown in total recording time between the three groups (P > .05), the total sleep time, sleep onset latency, sleep efficiency, and four stages (N1, N2, N3, and REM) of the study group 2 were significantly improved than those of the control group and the study group 1 (P < .05). Before treatment, there was no significant difference in serum levels of 5-HT, DA, and MT between the three groups (P > .05), while the three indexes were evidently lower than the control group and the study group 1 after four weeks of treatment (P < .05). During the treatment process, 1 case of mild dry mouth occurred in the study group who did not receive special treatment, and the incidence of adverse reactions was 1/48. In the control group, there were 3 cases of dry mouth, 1 case of constipation, 1 case of diarrhea, 1 case of decreased appetite, and 1 case of nausea, whose symptoms were not specially treated, with the incidence of adverse reactions of 7/48. Hence the incidence of adverse reactions in the study group was significantly lower than that in the control group (P < .05).
CONCLUSION: Combined treatment with modified Yangxin Anshen decoction and Western medicine improved sleep quality in elderly patients with schizophrenia and sleep disorders, which is available for wide clinical application.
The present invention relates to methods of treating disease by altering G  protein coupled receptor kinase (GRK) 6. This may be done by altering the expression or activity of the protein, for example. The present invention may be used for disease diagnosis, by detecting the expression or activity of GRK6. The present invention relates to a GRK6 deficient mouse, GRK6 splice variants, and methods of use. The present invention also relates to methods of identifying compounds that alter GRK6 activity. The present invention relates to disease treatment by altering GRK6 expression or activity.